Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study

BACKGROUND AND AIMS: We aimed to investigate the underlying mechanism of action of risankizumab, a monoclonal antibody targeting the IL-23 p19 subunit, previously reported to induce clinical and endoscopic remission in a randomised phase II study in patients with active Crohn’s disease. METHODS: Ile...

Descripción completa

Detalles Bibliográficos
Autores principales: Visvanathan, Sudha, Baum, Patrick, Salas, Azucena, Vinisko, Richard, Schmid, Ramona, Grebe, Kristie M, Davis, Justin W, Wallace, Kori, Böcher, Wulf O, Padula, Steven J, Fine, Jay S, Panés, Julián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225973/
https://www.ncbi.nlm.nih.gov/pubmed/30032288
http://dx.doi.org/10.1093/ecco-jcc/jjy099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225973/
https://www.ncbi.nlm.nih.gov/pubmed/30032288
http://dx.doi.org/10.1093/ecco-jcc/jjy099

Ejemplares similares